Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Edwards Lifesciences (EW)
NYSEHealth CareMedical - DevicesSnapshot 2026-11-04
$100.82+1.46%
Close 2026-11-05 · 1-day change
NYSEHealth CareMedical - DevicesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
3.39 → 3.39 EPS · FY ending Dec 31, 2027 · 16 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 16 to 16; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for EW yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Adjusted EPS reaches at least $2.95 in FY 2026 | A primary condition in Edwards Lifesciences's published investment case. The stated target is >= $2.95. | Intact | EPS falls below $2.95 in FY 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a growth-oriented medical-device business with a sector tailwind, supported by strong recent financial performance. The long-term thesis is intact, but earnings quality is fragile and the signal has eased from favorable to mildly favorable.
EW is modestly expensive versus peers, and the valuation evidence shows expectations are broadly aligned with the business outlook. The evidence does not point to a large expectations gap, though the valuation leaves limited room for execution to weaken.
Near term, management’s stated priorities are on track: total sales, TAVR, and TMTT have grown, and guidance for each has increased. A recent earnings beat and raised guidance support the trajectory, but a guidance reversal would damage credibility; the evidence also notes a history of recent misses.
Over the next one to three years, the thesis hinges on sustaining roughly 10% annual company sales growth and continued expansion of TAVR and TMTT. Weakening employment data could raise recession concerns for healthcare names, while continued strong results and guidance from sector peers such as ABT, MDT, and SYK could support the sector backdrop.
The multi-year view remains intact, with strong growth execution balanced by fragile earnings quality and an expensive valuation. The key test is whether management sustains its raised growth outlook without a reversal. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A primary condition in Edwards Lifesciences's published investment case. The stated target is >= $6.5 billion. |
| Intact |
| Revenue falls below $6.5 billion in FY 2026 |
Revenue: $1.716B FY2026-Q3; GAAP. Published target: >= $6.5 billion. Annual target cannot be compared with a quarterly or TTM observation. Nov 4, 20261,715,500,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
TAVR sales grow at least 7% in FY 2026, reaching $1.2 billion in Q1 | TAVR sales expand steadily, reaching $1.2 billion in Q1 2026. | Intact | TAVR sales growth falls below 7% in FY 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 7 of 8 supplied quarters. Management reported: “Outlook Based on the company’s second quarter performance, Edwards is increasing its full-year 2026 sales growth rate guidance to 10% to 11% from 9% to 11%, TAVR product group sales growth guidance to 8% to 9% from 7% to 9%, and TMTT product group sales guidance to $760 to $780 million from $740 to $780 million.” “Edwards now expects full-year total company sales of $6.6 billion to $6.9 billion and TAVR sales of $4.75 billion to $5.0 billion at current exchange rates.” Delivery assessment Nov 3, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$3.38 → $3.39 · observed estimates
$7.43B → $7.44B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $3.38 | $7,430,097,595 | 16 / 21 |
| 2026-07-25 | $3.37 | $7,423,681,080 | 27 / 27 |
| 2026-07-26 | $3.37 | $7,423,681,080 | 27 / 27 |
| 2026-07-27 | $3.37 | $7,422,777,380 | 27 / 27 |
| 2026-07-28 | $3.38 | $7,435,572,660 | 16 / 21 |
| 2026-07-29 | $3.38 | $7,435,572,660 | 16 / 21 |
| 2026-07-30 | $3.38 | $7,414,786,800 | 16 / 22 |
| 2026-07-31 | $3.38 | $7,414,786,800 | 16 / 22 |
| 2026-08-01 | $3.38 | $7,414,786,800 | 16 / 22 |
| 2026-08-02 | $3.38 | $7,429,110,230 | 28 / 28 |
| 2026-08-03 | $3.38 | $7,429,113,950 | 28 / 28 |
| 2026-08-04 | $3.38 | $7,417,342,355 | 16 / 22 |
| 2026-08-05 | $3.38 | $7,429,113,950 | 28 / 28 |
| 2026-08-06 | $3.38 | $7,417,342,355 | 16 / 22 |
| 2026-08-07 | $3.38 | $7,417,342,355 | 16 / 22 |
| 2026-08-08 | $3.38 | $7,429,113,950 | 28 / 28 |
| 2026-08-09 | $3.38 | $7,429,113,950 | 28 / 28 |
| 2026-08-10 | $3.38 | $7,429,113,950 | 28 / 28 |
| 2026-08-11 | $3.38 | $7,417,342,355 | 16 / 22 |
| 2026-08-12 | $3.38 | $7,417,342,355 | 16 / 22 |
| 2026-08-13 | $3.38 | $7,429,113,950 | 28 / 28 |
| 2026-08-14 | $3.38 | $7,417,342,355 | 16 / 22 |
| 2026-08-15 | $3.38 | $7,417,342,355 | 16 / 22 |
| 2026-08-16 | $3.38 | $7,417,342,355 | 16 / 22 |
| 2026-08-17 | $3.38 | $7,417,342,355 | 16 / 22 |
| 2026-08-18 | $3.38 | $7,417,342,355 | 16 / 22 |
| 2026-08-19 | $3.38 | $7,417,342,355 | 16 / 22 |
| 2026-08-20 | $3.38 | $7,418,548,511 | 16 / 22 |
| 2026-08-21 | $3.38 | $7,418,548,511 | 16 / 22 |
| 2026-08-22 | $3.38 | $7,418,548,511 | 16 / 22 |
| 2026-08-23 | $3.39 | $7,418,548,511 | 16 / 22 |
| 2026-08-24 | $3.39 | $7,418,548,511 | 16 / 22 |
| 2026-08-25 | $3.39 | $7,418,548,511 | 16 / 22 |
| 2026-08-26 | $3.39 | $7,418,548,511 | 16 / 22 |
| 2026-08-27 | $3.39 | $7,418,548,511 | 16 / 22 |
| 2026-08-28 | $3.39 | $7,418,548,511 | 16 / 22 |
| 2026-08-29 | $3.39 | $7,418,548,511 | 16 / 22 |
| 2026-08-30 | $3.39 | $7,418,565,950 | 16 / 22 |
| 2026-08-31 | $3.39 | $7,418,565,950 | 16 / 22 |
| 2026-09-01 | $3.39 | $7,418,565,950 | 16 / 22 |
| 2026-09-02 | $3.39 | $7,418,735,173 | 16 / 22 |
| 2026-09-03 | $3.39 | $7,418,735,173 | 16 / 22 |
| 2026-09-04 | $3.39 | $7,418,735,173 | 16 / 22 |
| 2026-09-05 | $3.39 | $7,418,735,173 | 16 / 22 |
| 2026-09-06 | $3.39 | $7,418,735,173 | 16 / 22 |
| 2026-09-07 | $3.39 | $7,418,735,173 | 16 / 22 |
| 2026-09-08 | $3.39 | $7,418,735,173 | 16 / 22 |
| 2026-09-09 | $3.39 | $7,418,735,173 | 16 / 22 |
| 2026-09-10 | $3.39 | $7,418,735,173 | 16 / 22 |
| 2026-09-11 | $3.38 | $7,418,719,788 | 16 / 22 |
| 2026-09-12 | $3.39 | $7,418,412,096 | 16 / 22 |
| 2026-09-13 | $3.39 | $7,418,412,096 | 16 / 22 |
| 2026-09-14 | $3.39 | $7,418,412,096 | 16 / 22 |
| 2026-09-15 | $3.39 | $7,418,412,096 | 16 / 22 |
| 2026-09-16 | $3.39 | $7,418,412,096 | 16 / 22 |
| 2026-09-17 | $3.39 | $7,418,412,096 | 16 / 22 |
| 2026-09-18 | $3.39 | $7,418,412,096 | 16 / 22 |
| 2026-09-19 | $3.39 | $7,418,412,096 | 16 / 22 |
| 2026-09-20 | $3.39 | $7,418,412,096 | 16 / 22 |
| 2026-09-21 | $3.39 | $7,418,412,096 | 16 / 22 |
| 2026-09-22 | $3.39 | $7,418,412,096 | 16 / 22 |
| 2026-09-23 | $3.39 | $7,418,412,096 | 16 / 22 |
| 2026-09-24 | $3.39 | $7,418,412,096 | 16 / 22 |
| 2026-09-25 | $3.39 | $7,418,412,096 | 16 / 22 |
| 2026-09-26 | $3.39 | $7,418,412,096 | 16 / 22 |
| 2026-09-27 | $3.39 | $7,418,412,096 | 16 / 22 |
| 2026-09-28 | $3.39 | $7,418,412,096 | 16 / 22 |
| 2026-09-29 | $3.39 | $7,418,412,096 | 16 / 22 |
| 2026-09-30 | $3.39 | $7,418,412,096 | 16 / 22 |
| 2026-10-01 | $3.39 | $7,418,719,788 | 16 / 22 |
| 2026-10-02 | $3.39 | $7,418,723,634 | 16 / 22 |
| 2026-10-03 | $3.39 | $7,418,723,634 | 16 / 22 |
| 2026-10-04 | $3.39 | $7,418,723,634 | 16 / 22 |
| 2026-10-05 | $3.39 | $7,418,723,634 | 16 / 22 |
| 2026-10-06 | $3.39 | $7,420,108,250 | 16 / 22 |
| 2026-10-07 | $3.39 | $7,420,108,250 | 16 / 21 |
| 2026-10-08 | $3.39 | $7,420,108,250 | 16 / 21 |
| 2026-10-09 | $3.39 | $7,420,108,250 | 16 / 21 |
| 2026-10-10 | $3.39 | $7,420,108,250 | 16 / 21 |
| 2026-10-11 | $3.39 | $7,420,108,250 | 16 / 21 |
| 2026-10-12 | $3.39 | $7,420,108,250 | 16 / 21 |
| 2026-10-13 | $3.39 | $7,420,112,996 | 16 / 21 |
| 2026-10-14 | $3.39 | $7,420,121,204 | 16 / 21 |
| 2026-10-15 | $3.39 | $7,420,121,204 | 16 / 21 |
| 2026-10-16 | $3.39 | $7,420,557,227 | 16 / 21 |
| 2026-10-17 | $3.39 | $7,420,557,227 | 16 / 21 |
| 2026-10-18 | $3.39 | $7,420,388,004 | 16 / 21 |
| 2026-10-19 | $3.39 | $7,420,388,004 | 16 / 21 |
| 2026-10-20 | $3.39 | $7,420,388,004 | 16 / 21 |
| 2026-10-21 | $3.39 | $7,420,388,004 | 16 / 21 |
| 2026-10-22 | $3.39 | $7,420,388,004 | 16 / 21 |
| 2026-10-23 | $3.39 | $7,420,388,004 | 17 / 21 |
| 2026-10-24 | $3.39 | $7,420,388,004 | 17 / 21 |
| 2026-10-25 | $3.39 | $7,420,388,004 | 17 / 22 |
| 2026-10-26 | $3.39 | $7,420,388,004 | 17 / 22 |
| 2026-10-27 | $3.39 | $7,420,388,004 | 17 / 22 |
| 2026-10-28 | $3.39 | $7,420,718,773 | 17 / 22 |
| 2026-10-29 | $3.39 | $7,420,718,773 | 17 / 22 |
| 2026-10-30 | $3.39 | $7,420,718,773 | 17 / 22 |
| 2026-10-31 | $3.39 | $7,420,718,773 | 17 / 22 |
| 2026-11-01 | $3.39 | $7,420,718,773 | 17 / 22 |
| 2026-11-02 | $3.39 | $7,420,718,773 | 17 / 22 |
| 2026-11-03 | $3.39 | $7,454,766,825 | 17 / 22 |
| 2026-11-04 | $3.39 | $7,438,822,875 | 16 / 21 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 24 Buy / Strong Buy · 7 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 1 recorded
1 raises · 0 cuts · 0 unchanged · 1 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.